VEGFA and neoplasm: The MDSCs can inhibit T cell-mediated tumor acquired immune responses with overexpression of Arg1, iNOS, and Ros, suppress NK cell cytotoxicity by inhibiting NKG2D and IFN-c, and facilitate angiogenesis by releasing vascular endothelial growth factor (VEGF), MMPs, and TGF-β [46].